SPEAKER BIOGRAPHY:

Stefan Adler is the Vice President of Consulting Services at H3 Consulting. Stefan has over 20 years of experience working for law firms, corporations, discovery software providers and consultancies. Stefan develops repeatable discovery processes that help clients successfully manage legal disputes, helping clients to lower costs and risks associated with document management while preserving high levels of confidentiality. He manages review teams, develops operational documents, and helps train staff to ensure that planned improvement realize projects realize benefits from planned improvements. He has extensive experience in supporting emerging companies.

LEARNING OBJECTIVES:

• How does a data collaboration plan protect IP?
• Why Your Company Should Develop a Data Collaboration Plan - Understanding the Business
• Goals and Risks of Collaboration
• Define collaboration needs first! Know your needs before you plan your solution.
• Planning early to preserve maximum options
• Implementing and Managing the Plan

SPEAKER BIOGRAPHY:

Andy Thorson is the former Corporate Vice President of Business Development at Varian Medical Systems. Thorson is Senior Executive with 25 years experience in merchant banking, private equity advisory, medical device/capital equipment, financial management, business development, heavy industry and start-ups. He has extensive experience in Asian and European markets. Thorson has an MBA from the University of Chicago and an AB in International Relations from Stanford University.

LEARNING OBJECTIVES:

• Why Every Company Should Have an Exit Path and Plan
• Information Integrity Concerns
• Regulatory Compliance
• Intellectual Property Protection
• HR Considerations
• Contracts and Liabilities
• Financial History, Projections and Reality
• Operations, Markets and Customers
• A Deal Process Should Not Hobble Your Business

SPEAKER BIOGRAPHY:

Linda M. Pullan, Ph.D. offers biotech and pharmaceutical companies consulting in all aspects of partnering through Pullan Consulting (www.pullanconsulting.com). Linda has a Ph.D. in Biochemistry and a B.S. in Chemistry. Linda has more than 20 years of drug industry experience, beginning in drug discovery at Monsanto/Searle/now Pfizer and ICI/Zeneca/now AstraZeneca. After doing licensing at what is now AstraZeneca, Dr. Pullan continued as head of oncology and hematology licensing for Amgen. She then joined Kosan Biosciences as VP of Business Development and experienced all the tasks of out-licensing and business development in a small company. For several years, she has been providing companies help in identification, evaluation, valuation, negotiation and strategy for partnering in or out. She has an extensive deal sheet ranging from company acquisitions to Phase III compounds and from preclinical candidates to technologies, with both in- and out-licensing. She writes a free monthly newsletter Pullan's Pieces, with tidbits of science and business for about 3,600 readers. Interested readers may sign up by sending an email to lpullan@msn.com.

LEARNING OBJECTIVES:

• Basics of Valuation
• Dealmaking Process
• Preparations for Negotiations
• Term sheet Details

SPEAKER BIOGRAPHY:

Kevin has a 15+ year track record of achievement across financial operations, M&A, venture capital, and investment management. As a partner at PwC, Kevin advised small private as well as Fortune 50 companies on M&A strategy, process and execution. He took a lead role in developing and scaling a $50M merger integration practice across the US and in Europe. At 3i Venture Capital, Kevin led/co-led investments in 15 technology businesses. As a Board member on these investments, he demonstrated expertise in CEO recruitment, compensation issues, financing negotiation, growth strategy, and profitable exit management. In 2009, Kevin successfully spun out 12 portfolio companies from 3i in a secondary transaction to create Maywood Capital Partners. At Centaur Partners, Kevin is focused on assisting selling companies prepare for M&A.

LEARNING OBJECTIVES:

• Latest M&A trends
• Why it's critical to be fully prepared
• Reality of due diligence
• Avoiding the deal killing traps

WEBINAR DATE: July 12, 2011 PRESENTATION OVERVIEW: Today's legal teams are faced with an increasingly complex electronic discovery environment and are often challenged with ensuring that appropriate decisions are made in collecting, processing, reviewing and producing relevant evidence. Taking appropriate steps to instill quality control at each point in the process is the first step; but achieving quality across the discovery spectrum requires well-defined processes, solid documentation, strong collaboration capabilities and a means to measure results. How do you show that you issued legal holds to the right people in a timely manner? How do you document the collection, processing and transfer of data from custodian through review and on to production? What do you look to when documenting the steps taken, prior to certifying results to courts or regulators? Mr. Lee will share insights for driving quality during the discovery cycle, including ideas on what smart lawyers should look for when certifying completeness of discovery.

SPEAKER BIOGRAPHY:

Ed Lee is an attorney and Senior Manager in the Deloitte Financial Advisory Services Discovery Advisory Services practice. He regularly assists clients with developing electronic discovery programs and implementing solutions for information management and litigation readiness.

Mr. Lee has over a decade of hands-on experience helping corporations prepare for and respond to conflict and compliance challenges, both through robust corporate policies and state-of-the-art technology.

SPEAKER BIOGRAPHY:

Duane J. Roth is Chief Executive Officer and Member of the Board of CONNECT. CONNECT is the globally recognized nonprofit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. CONNECT has been directly involved with over 2,000 companies since its inception in 1985 and these companies have secured over $10 billion in funding. Prior to joining CONNECT, Mr. Roth founded Alliance Pharmaceutical Corp., where he served as Chairman of the Board. Prior to Alliance, he held senior management positions at Johnson & Johnson and Wyeth (now Pfizer) operating companies. He has served as a Member of the Board of Directors and executive committees of the Biotechnology Industry Organization (BIO), the California Healthcare Institute (CHI) and BIOCOM (past Chair). Mr. Roth was appointed to the oversight board of the California Institute of Regenerative Medicine (CIRM) by Governor Arnold Schwarzenegger in 2006 and was elected Vice Chairman in 2009.

PRESENTATION OVERVIEW:

Notwithstanding a pleasant uptick in early-stage investing in 2010 and early 2011, later-stage venture financings continue to employ mechanics designed to incentivize investment behavior, address valuation realities and realign cap tables. A majority of the effort in these financings can be spent architecting financing mechanics and constructing and analyzing the resultant pro forma cap tables. This webinar will briefly identify a number of the most frequently observed mechanics and illustrate the power of capitalization modeling in these transactions.

SPEAKER BIOGRAPHY:

Mr. Harris heads the Technology Group of Morrison & Foerster's Emerging Companies and Venture Capital group. He represents venture capital firms, corporate strategic investors and angel investors in their investments in start-up companies at all phases of development, ranging from seed stage convertible debt or equity investments to preferred stock financings to strategic loans coupled with commercial agreements and acquisition options.

He also represents start-ups from incorporation through acquisition or initial public offering in matters including financing, equity incentive compensation and technology development and commercialization. He specializes in modeling complex capital structures, financing scenarios and liquidity events.

Prior to practicing law, he designed, programmed, and implemented software systems for clients in the financial services industry. He holds a degree in computer science from Princeton University and graduated from the Northwestern University School of Law.

AGENDA:

• What are some of the keys to doing successful deals in Asia-Pacific?
• What are the major differences from doing deals in the Western Hemisphere?
• What major pitfalls do you need to avoid in order to complete a successful transaction?

SPEAKER BIOGRAPHY:

Charles Comey is a corporate finance partner in Morrison/Foerster's Palo Alto, California office. His experience includes working in Asia for 16 years, where he served as Managing Partner of the firm's Shanghai office and also worked in Morrison & Foerster's Tokyo office where he specialized in cross-border mergers and acquisitions and strategic alliances.

Currently, as co-chair of the China Private Equity Group, he now advises clients on venture capital, private equity, mergers and acquisitions and strategic alliances, as well as RMB fund formation and Cleantech matters. He has also counseled public companies on FCPA issues and internal investigations.

Mr. Comey is recommended as a leading lawyer for China-based private equity and venture capital investments by IFLR 1000 and PLC Cross-border Which Lawyer? for his expertise in private equity in Asia and China. He reads and speaks Mandarin.

AGENDA:

• Current M&A market dynamics
• Getting on the radar of acquirers
• How large acquirers behave
• Your window of opportunity to sell your company
• Working with advisors
• Preparation for a sale

SPEAKER BIOGRAPHY:

For the last twenty years Brian Moriarty has helped companies grow inorganically (M&A, alliances, licensing, investments) both as an investment banker and a corporate development executive. Most recently Brian was Vice President of Business Affairs at Sun Microsystems.

In this position, Brian helped Sun acquire twenty companies ranging in valuation size from several million to multi-billion dollars, including such notable companies as MySQL AB, Storage Technology Corporation and SeeBeyond Technology Corporation. Brian also helped Sun sell itself to Oracle Corporation in a transaction that closed in January 2010.

Brian is currently consulting companies in the areas of M&A strategy, execution, acquisition, and integration.

Since most company exits are likely to be via merger or acquisition, it's important to understand how preparing for the event ahead of time can significantly increase the efficiency and speed up the process, and potentially even affect its success. Mike Bates, our guest speaker for this webinar, is the former CFO of four Life Science companies that all achieved favorable exits. Mike will share his expertise in establishing processes, systems and management activities prior to any transaction, and explain the most important reasons for doing so.

AGENDA

• The importance of starting your planning early
• Key CFO considerations in choosing and hiring investment bankers
• Get the team ready to do management presentations
• As CFO, you own the diligence process and data room
• Criteria to consider in selecting and setting up a data room
• Audience Q&A

SPEAKER BIOGRAPHY

Mike Bates has had his fair share of M&A transactions. Over a twelve year span, Mr. Bates was CFO of four companies that were sold – Penederm Inc. (public), Collagen Aesthetics (public), Silicon Genetics (private) and St. Francis Medical Technologies, Inc. (private). He lived through the transition from physical data rooms to today's state of the art virtual data rooms.

In one of his transactions, six possible buyers started diligence and only one submitted a final offer. Mike has accumulated a few preparation tips and techniques that he will share with you in this webinar. Mr. Bates is a C.P.A. (inactive), and holds a B.S. in Business Administration from California State University, East Bay and an M.B.A. in Finance from the University of California at Berkeley.

He currently serves as Audit Committee Chair for two medical device companies and is an active angel investor.